Oryzon Genomics, member of CataloniaBio & HealthTech, has announced that it is developing a new molecule for the treatment of personality disorders. This new molecule, called ORY-304, acts as a selective inhibitor of LSD1, an enzyme involved in the epigenetic regulation of genes related to behaviour and emotions. Personality disorders are a group of mental disorders that affect how people perceive, think, and relate to others. These disorders are difficult to treat and have a significant impact on the quality of life of those affected.
ORY-304 aims to regulate gene expression associated with personality disorders and improve associated symptoms. The development of this molecule represents a significant advancement in the treatment of these disorders, as there is currently no approved drug specifically for this condition.
ORY-304 is currently in the preclinical phase, and it is expected that clinical studies will be conducted in the coming years. Oryzon Genomics is a leading company in the development of epigenetic therapies and has been recognized for its innovation in the field of health.
Comments